» Articles » PMID: 17289435

Frequency of EmbB Codon 306 Mutations in Ethambutol-susceptible and -resistant Clinical Mycobacterium Tuberculosis Isolates in Kuwait

Overview
Date 2007 Feb 10
PMID 17289435
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Setting: Recent reports of embB306 mutations in ethambutol-resistant and ethambutol-susceptible drug-resistant strains of Mycobacterium tuberculosis have questioned the significance of these mutations in conferring resistance to ethambutol (EMB).

Objective: To determine the occurrence of embB306 mutations in all EMB-resistant and -susceptible drug-resistant M. tuberculosis strains isolated during a specified period at a single geographical location.

Design: Twenty-five pansusceptible, all EMB-resistant and -susceptible M. tuberculosis strains resistant to other first-line drugs isolated in Kuwait during 2000-2003 were analyzed. The embB306 mutations were detected by PCR-restriction fragment length polymorphism and DNA sequencing. The PCR-based methods were also used for determining strain relatedness.

Results: None of the pansusceptible M. tuberculosis strains contained a mutation at embB306. Fifteen of 50 (30%) EMB-resistant strains but only three of 122 (2%) EMB-susceptible isolates resistant to other first-line drugs contained a mutated embB306. The EMB-susceptible isolates with embB306 mutation were resistant to isoniazid plus other drug(s). The isolates carrying similar mutations were genotypically distinct strains.

Conclusions: The frequency of embB306 mutations in EMB-resistant strains compared to EMB-susceptible M. tuberculosis isolates resistant to other drugs was 15 times higher. Association of embB306 mutations in EMB-susceptible strains with isoniazid resistance and inherent problems associated with phenotypic EMB susceptibility testing suggest that these strains may actually be EMB-resistant.

Citing Articles

Using Microfluidic Chip and Allele-Specific PCR to Rapidly Identify Drug Resistance-Associated Mutations of .

Chen S, Liu H, Li T, Lai W, Liu L, Xu Y Infect Drug Resist. 2023; 16:4311-4323.

PMID: 37424666 PMC: 10327919. DOI: 10.2147/IDR.S410779.


Mutations and insights into the molecular mechanisms of resistance of Mycobacterium tuberculosis to first-line.

Rossini N, Dias M Genet Mol Biol. 2023; 46(1 Suppl 2):e20220261.

PMID: 36718771 PMC: 9887390. DOI: 10.1590/1678-4685-GMB-2022-0261.


Cytokine upsurge among drug-resistant tuberculosis endorse the signatures of hyper inflammation and disease severity.

Sampath P, Rajamanickam A, Thiruvengadam K, Natarajan A, Hissar S, Dhanapal M Sci Rep. 2023; 13(1):785.

PMID: 36646786 PMC: 9842614. DOI: 10.1038/s41598-023-27895-8.


Increasing prevalence of resistance to second-line drugs among multidrug-resistant Mycobacterium tuberculosis isolates in Kuwait.

Al-Mutairi N, Ahmad S, Mokaddas E Sci Rep. 2021; 11(1):7765.

PMID: 33833390 PMC: 8032671. DOI: 10.1038/s41598-021-87516-0.


Drug-Resistant Mycobacterium tuberculosis Isolates from New and Previously Treated TB Patients in China, 2017-2019.

Chun Z, Jun J Rev Soc Bras Med Trop. 2021; 54:e0728-2020.

PMID: 33759925 PMC: 8008859. DOI: 10.1590/0037-8682-0728-2020.